Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ProMIS Neurosciences Inc. (PMN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/17/2025: PMN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -43.95% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.34M USD | Price to earnings Ratio 5.56 | 1Y Target Price 5.78 |
Price to earnings Ratio 5.56 | 1Y Target Price 5.78 | ||
Volume (30-day avg) 58618 | Beta -0.08 | 52 Weeks Range 0.47 - 2.37 | Updated Date 06/19/2025 |
52 Weeks Range 0.47 - 2.37 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -124.39% | Return on Equity (TTM) -19.56% |
Valuation
Trailing PE 5.56 | Forward PE - | Enterprise Value 7947243 | Price to Sales(TTM) 5168.19 |
Enterprise Value 7947243 | Price to Sales(TTM) 5168.19 | ||
Enterprise Value to Revenue 3868.08 | Enterprise Value to EBITDA -1.74 | Shares Outstanding 32689200 | Shares Floating 17658374 |
Shares Outstanding 32689200 | Shares Floating 17658374 | ||
Percent Insiders 27.61 | Percent Institutions 28.56 |
Analyst Ratings
Rating 4.67 | Target Price 5.78 | Buy 1 | Strong Buy 2 |
Buy 1 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ProMIS Neurosciences Inc.
Company Overview
History and Background
ProMIS Neurosciences Inc. is a biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). Founded to address the need for more effective therapies for these diseases.
Core Business Areas
- Drug Discovery: Discovery of antibody therapeutics against misfolded proteins in neurodegenerative diseases.
- Preclinical Development: Advancing antibody candidates through preclinical testing.
- Partnerships and Licensing: Establishing partnerships to advance clinical development and commercialization.
Leadership and Structure
ProMIS Neurosciences Inc. is led by a team of scientists and business professionals with expertise in neurodegenerative disease research and drug development. The organizational structure includes research, development, and corporate functions.
Top Products and Market Share
Key Offerings
- PMN310: A monoclonal antibody targeting toxic amyloid-beta oligomers in Alzheimer's disease. Currently in preclinical development. Competitors include Biogen, Eisai, Eli Lilly.
- ALS Programs: Developing antibody therapeutics for ALS. Competitors include Amylyx Pharmaceuticals and Biogen.
Market Dynamics
Industry Overview
The neurodegenerative disease market is large and growing, driven by an aging population and increasing prevalence of diseases such as Alzheimer's and Parkinson's. There is a significant unmet need for effective therapies.
Positioning
ProMIS Neurosciences Inc. focuses on targeting toxic protein aggregates, a differentiated approach in the neurodegenerative disease field. Competitive advantages include its discovery platform and selective antibody candidates.
Total Addressable Market (TAM)
The global Alzheimer's disease market is estimated to reach billions of dollars. ProMIS Neurosciences Inc. aims to capture a portion of this market with its targeted antibody therapeutics.
Upturn SWOT Analysis
Strengths
- Proprietary discovery platform
- Selective antibody candidates
- Experienced leadership team
- Focus on disease-modifying therapies
Weaknesses
- Early stage of development
- High dependence on financing
- Limited clinical data
- Small company size
Opportunities
- Partnerships with larger pharmaceutical companies
- Advancement of clinical programs
- Expansion into new indications
- Increasing prevalence of neurodegenerative diseases
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- ESAI
Competitive Landscape
ProMIS Neurosciences Inc. faces competition from larger pharmaceutical companies with more resources. However, its focus on targeting toxic protein aggregates provides a differentiated approach.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expansion of research programs and preclinical development activities.
Future Projections: Future growth is contingent on successful clinical development of antibody candidates and partnerships. Analyst estimates vary depending on program progress.
Recent Initiatives: Focus on advancing PMN310 into clinical trials and expanding collaborations.
Summary
ProMIS Neurosciences Inc. is an early-stage biotechnology company with a promising approach to treating neurodegenerative diseases. Its strengths lie in its proprietary technology and selective antibody candidates. However, it faces challenges related to financing, clinical development, and competition. Success hinges on advancing its programs and securing partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be complete or accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ProMIS Neurosciences Inc.
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2007-07-17 | CEO, President, Compliance Officer & Director Mr. Neil K. Warma M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | |
Full time employees 7 | |||
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.